Protein Summary
Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit ...more
- ENST00000256443
- ENSP00000256443
- ENSG00000134058
- ENST00000615305
- ENSP00000479116
- ENSG00000277273
- CAK
- CAK1
- CDKN7
- MO15
- STK1
- CAK
- CAK1
- HCAK
- MO15
- STK1
- CDKN7
- p39MO15
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
molecular function | 1 | ||
small molecule | 1 | ||
biological process | 0.95 | ||
hub protein | 0.88 | ||
transcription factor perturbation | 0.88 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 344.91 (req: < 5)
Gene RIFs: 62 (req: <= 3)
Antibodies: 756 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 344.91 (req: >= 5)
Gene RIFs: 62 (req: > 3)
Antibodies: 756 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 28
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 59
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1